Brown Advisory Inc. Acquires 107,324 Shares of Sanofi $SNY

Brown Advisory Inc. lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 34.1% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 421,960 shares of the company’s stock after buying an additional 107,324 shares during the period. Brown Advisory Inc.’s holdings in Sanofi were worth $20,385,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of SNY. GeoWealth Management LLC raised its stake in Sanofi by 14.7% during the second quarter. GeoWealth Management LLC now owns 21,159 shares of the company’s stock worth $1,022,000 after acquiring an additional 2,704 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Sanofi by 14.8% during the 2nd quarter. First Trust Advisors LP now owns 869,201 shares of the company’s stock valued at $41,991,000 after purchasing an additional 112,091 shares during the last quarter. Kennedy Capital Management LLC bought a new stake in shares of Sanofi during the 2nd quarter valued at approximately $616,000. EverSource Wealth Advisors LLC increased its position in Sanofi by 36.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after purchasing an additional 875 shares in the last quarter. Finally, CW Advisors LLC lifted its stake in Sanofi by 110.7% in the 2nd quarter. CW Advisors LLC now owns 13,753 shares of the company’s stock valued at $664,000 after purchasing an additional 7,226 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors.

Sanofi Stock Up 1.3%

Shares of NASDAQ:SNY opened at $49.53 on Friday. The firm has a market cap of $121.62 billion, a P/E ratio of 11.60, a P/E/G ratio of 1.35 and a beta of 0.44. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The business has a fifty day simple moving average of $49.90 and a 200 day simple moving average of $49.18. The company has a quick ratio of 0.30, a current ratio of 1.06 and a debt-to-equity ratio of 0.16.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Friday, October 24th. The company reported $2.91 earnings per share for the quarter, beating the consensus estimate of $1.60 by $1.31. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $15.46 billion during the quarter, compared to analysts’ expectations of $12.62 billion. During the same quarter in the prior year, the firm posted $2.25 earnings per share. The business’s quarterly revenue was down 7.5% on a year-over-year basis. Analysts predict that Sanofi will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SNY has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Sanofi in a research note on Monday, December 1st. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.